← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-11 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Ixazomib and Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 1

Daratumumab (JNJ-54767414, JNJ-54767414 (Daratumumab))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

JS001+Bevacizumab (JS001+Bevacizumab)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, KF-0210 (dosage RP2D) + Atezolizumab, dosage RP2D)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-1, KF-0210 (dosage RP2D-1) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-2, KF-0210 (dosage RP2D-2) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMalaria Research and Training C…Phase 2

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

Plasmodium Falciparum Infection; Malaria · Plasmodium Falciparum Infection

#PlasmodiumFalciparumInfection#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleShanghai Pulmonary Hospital, Sh…Phase 2

LM-108+Sintilimab (LM-108+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleOslo University HospitalPhase 2

pembrolizumab (Keytruda, LTX-315 + pembrolizumab)

Melanoma Stage IIIB-IV · Melanoma Stage IIIB-IV

#MelanomaStageIIIB-IV#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMerrimack PharmaceuticalsPhase 1

trastuzumab (Herceptin, Lapatinib +/- Trastuzumab and MM-111)

HER-2 Gene Amplification · HER-2 Gene Amplification

#HER-2GeneAmplification#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBerufsverband Niedergelassener …Phase 2

trastuzumab (Herceptin, Lapatinib plus trastuzumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleMerrimack PharmaceuticalsPhase 1

trastuzumab (Herceptin, Lapatinib, trastuzumab, paclitaxel, and MM-111)

HER-2 Gene Amplification · HER-2 Gene Amplification

#HER-2GeneAmplification#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

Lemzoparlimab (Lemzoparlimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGeorgetown UniversityPhase 1

Lenalidomide, Ibrutinib, Rituximab (Lenalidomide, Ibrutinib, Rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Lenvatinib plus Pembrolizumab)

Liver Neoplasm Malignant Primary; Cholangiocarcinoma · Liver Neoplasm Malignant Primary

#LiverNeoplasmMalignantPrimary#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleThe First Hospital of Jilin Uni…Phase 2

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleIovance Biotherapeutics, Inc.Phase 3

pembrolizumab (Keytruda, Lifileucel plus Pembrolizumab)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING

54 / 92 페이지

← 이전다음 →